Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1420 - Outcomes of systemic therapy for advanced triple-negative breast cancer: a single centre experience.


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Nicolò Battisti


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


N. Battisti1, D. Okonji1, T. Manickavasagar1, K. Mohammed2, M. Allen1, A. Ring1

Author affiliations

  • 1 Breast Unit, The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Research And Development Department, The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB


Abstract 1420


Systemic treatment outcomes for advanced triple-negative breast cancer (aTNBC) are worse compared to other disease subtypes, due to aggressive behaviour, heterogeneity and lack of molecular targets. Many options are under investigation although most patients receive standard cytotoxic chemotherapy. We aimed to provide better insight into the efficacy of different lines of therapy for aTNBC (overall response rate [ORR], median progression-free survival [mPFS] and median overall survival [mOS]) to better inform discussion with patients, decision-making and referral for clinical trials.


We retrospectively identified 268 patients diagnosed with aTNBC from 01/12/2011 to 30/11/2016 from our electronic records. Patients’ and tumour characteristics were recorded, along with systemic treatment outcomes. Chi-squared/Fishers exact test and Kaplan-Meier statistical methods were utilised.


186 patients treated with ≥1 line of palliative systemic treatment were eligible for the analysis with a median age at 55 (range 26-91). 53.8% had ECOG Performance Status 0 and 69.9% visceral involvement. 38.6% had a disease-free interval (DFI)


The response rates observed in this population of patients are similar to those observed in published clinical trials. However, the PFS rates are short, and as a result early consideration for inclusion in clinical trials of novel approaches can be justified in these patients.

Clinical trial identification

Legal entity responsible for the study

Nicolò Matteo, Luca Battisti




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.